Logo

Tanvex Presents Results of TX05 (biosimilar- trastuzumab) in P-III Study for the Treatment of HER2-Positive Early Stage Breast Cancer at ESMO 2021

Share this
Tanvex Presents Results of TX05 (biosimilar- trastuzumab) in P-III Study for the Treatment of HER2-Positive Early Stage Breast Cancer at ESMO 2021

Tanvex Presents Results of TX05 (biosimilar- trastuzumab) in P-III Study for the Treatment of HER2-Positive Early Stage Breast Cancer at ESMO 2021

Shots:

  • The P-III study evaluates TX05 (biosimilar- trastuzumab) vs Herceptin in 809 patients with HER2-positive early-stage breast cancer
  • The results showed that the proportions of patients that meet pCR criteria for equivalence were highly similar b/w TX05 (48.8%) and TRA (45.3%) cohorts; ORR (84.3%) & (85.0%); CR; PR and stable disease were also highly similar- patients experienced TEAEs (62.4% vs 62.5%)- respectively
  • Additionally- the therapy was well tolerated & the safety profile was consistent with the known profile of TRA

  | Ref: Centre for Biosimilar | Image: Tanvex Biopharma

Click here to­ read the full press release 

Tuba

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions